AstraZeneca Chooses IntraLinks as its Standard Hub for Clinical Drug Trials

New York, March 18, 2003
IntraLinks, Inc., the leading provider of secure digital workspaces to the financial services and pharmaceutical communities, today announced that AstraZeneca will use IntraLinks as a secure hub to facilitate the exchange of information with investigator sites and other participants throughout the clinical trial process.

"In clinical trials that take years and cost millions of dollars, every day saved can result in therapeutic alternatives for patients and significant cost savings for the company. IntraLinks has emerged as one solution that could produce concrete time and cost savings, and we are now implementing its use in clinical trials," said Glenn Gormley, M.D., PhD, Vice President, U.S. Clinical Development, AstraZeneca. "Through the use of IntraLinks' services, we will greatly enhance information exchange among IRBs, CROs, investigators and trial managers, and hope to accelerate the process significantly. We anticipate that the results of this initiative will be enormously successful."

Pharmaceutical companies use IntraLinks' Internet-based services to communicate and deliver documentation pertaining to clinical trials, drug licensing, mergers and acquisitions and other complex, high-value business processes that require secure exchange of information across enterprise boundaries. IntraLinks provides a neutral third party environment that is fully hosted and includes 24-hour service and support. IntraLinks' service was designed to comply with FDA and ICH computer system validation requirements.

"Within the pharmaceutical community, market-leaders like AstraZeneca are continuously seeking innovative ways to reduce the time necessary to bring drugs to market," said Richard Jenkins, General Manager of Life Sciences at IntraLinks. "IntraLinks is committed to providing the pharmaceutical industry with the service and technology needed to speed clinical trials through our drug development hub."

About AstraZeneca
AstraZeneca (AZN: NYSE) is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. In the United States, AstraZeneca is a $9.3 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit www.astrazeneca-us.com.

This press release contains forward-looking statements with respect to AstraZeneca's business. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see AstraZeneca's Annual Report for 2002.

About IntraLinks
IntraLinks (www.intralinks.com), the leading provider of digital workspaces, connects business communities and accelerates the intelligent flow of information and documents among participants. Through IntraLinks' secure, neutral, online environments, companies are better able to compete globally by accelerating essential business processes, simplifying communication, and fostering rapid workflow. IntraLinks is easily accessible anywhere, anytime using a web browser.

Since April 1997, more than 100,000 participants representing over 3,000 companies worldwide have used IntraLinks digital workspaces to communicate and collaborate on more than 10,000 projects and transactions. IntraLinks has been rapidly adopted by the financial services and pharmaceutical markets. Over 100 global companies are IntraLinks clients, including AstraZeneca Pharmaceuticals LP; Bank of America; Bank One; Bear Stearns; Deutsche Bank; Dresdner Kleinwort Wasserstein; Ernst & Young; FDIC; Houlihan Lokey Howard & Zukin; International Finance Corporation (World Bank Group); JPMorgan Chase; TD Securities; Thomas Weisel Partners; Wachovia Securities; and WestLB. Founded in June 1996, IntraLinks is headquartered in New York with offices in Boston and London.